Covid19
Conditions
Keywords
Nervous system, coronavirus, SARS-CoV-2, Nervous system symptoms
Brief summary
This study aim to prospectively evaluate the neuropsychiatric symptoms of patients infected with the SARS-CoV-2 virus by a standardized neuropsychiatric examination : the global CASE scale (Clinical Assessment Scale in Autoimmune Encephalitis), and the prevalence of disturbances of consciousness, focal neurological deficit, cognitive impairment, headache, anosmia, sleep disturbances, impaired autonomic nervous system and peritraumatic stress.
Interventions
OTHERNEURO +
The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score : * The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005) * the Peri traumatic distress inventory (Jehel et al., 2005) * and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004) Neuro + patients will also have a Brain MRI, cerebrospinal fluid analysis, EEG, as well as an ambulatory sleep recording and electromyography depending on the symptoms observed.
OTHERNEURO -
The participants will undergo several questionnaires after their classic clinical evaluation allowing to determine the Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score : * The dissociative peri-traumatic experiences questionnaire (Birmes et al., 2005) * the Peri traumatic distress inventory (Jehel et al., 2005) * and the Shortness, Trembling, Racing, Sweating (STRS) (Bracha et al., 2004)
Sponsors
University Hospital, Toulouse
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Intervention model description
This is an observational, prospective, cross-sectional and monocentric cohort study
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* Being hospitalized at the Toulouse University Hospital for a COVID-19 infection proven by a probable PCR or COVID-type examination on the chest scan * Have given oral consent for the collection of clinical neurological data * Be in a clinical state compatible with a 30-minute neurological examination * Be French-speaking * Be affiliated to a Social Security scheme
Exclusion criteria
* Refusal of the neurological examination * History of neurological pathology at a severe stage * Pregnant or breastfeeding woman * Persons with tutors or curators
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| percentage of patients in the Neuro + and Neuro- groups | Baseline T0 : inclusion visit | The percentage is deducted from the score on a global scale by the Clinical Assessment Scale in Autoimmune Between 0 and 1, patients will be classified in the Neuro group, if this score is greater than or equal to 2, patients will be classified in the Neuro + group. |
Countries
France
Outcome results
None listed